Clinical Trial Update: Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating mesenchymal stem cells in inflammation-resolution for COVID-19–induced ARDS. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: ARDS, COVID-19 | Phase 2 | Status: UNKNOWN